← The Wire
ZNTLNasdaq
Zentalis Pharmaceuticals, Inc.
Pharmaceutical Preparations · CIK 1725160
Developing azenosertib, a WEE1 inhibitor, for ovarian cancer and other tumor types
red 8-K · 90d
$267M
Market cap
$4.61
Last close
+14.1%
1D
+25.6%
5D
2.8M
Volume
Price · last 39 sessions+15.3%
May 4L $3.52 · H $4.61Jun 29
164
Total filings
Jun 18, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 18, 2026DEFA14ADEFA14AMay 27, 20268-KExecutive ChangeMay 27, 20268-KReg FD Disclosure · Company UpdateMay 21, 202610-Q10-QMay 12, 20268-KResults of Operations · Reg FD DisclosureMay 12, 20268-KReg FD Disclosure · Company UpdateMay 5, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 20268-KReg FD DisclosureApr 17, 20268-KReg FD Disclosure · Company UpdateApr 9, 202610-K10-KMar 26, 20268-KResults of OperationsMar 26, 20268-KReg FD Disclosure · Company UpdateJan 9, 2026SC 13D/ASC 13D/AJan 2, 20268-KExecutive Change · Company UpdateDec 15, 2025SC 13D/ASC 13D/ADec 15, 202510-Q10-QNov 10, 20258-KResults of Operations · Reg FD DisclosureNov 10, 20258-KExecutive Change · Reg FD DisclosureAug 26, 202510-Q10-QAug 6, 20258-KResults of Operations · Reg FD DisclosureAug 6, 20258-KShareholder VoteJun 18, 20258-KReg FD DisclosureJun 2, 2025DEFA14ADEFA14AMay 23, 20258-KReg FD DisclosureMay 20, 202510-Q10-QMay 14, 20258-KResults of OperationsMay 14, 2025DEFA14ADEFA14AApr 30, 2025DEF 14ADEF 14AApr 30, 20258-KReg FD DisclosureApr 28, 20258-KResults of OperationsMar 26, 202510-K10-KMar 26, 20258-KReg FD DisclosureMar 17, 20258-KReg FD Disclosure · Company UpdateJan 29, 20258-KExit / Disposal Costs · Reg FD DisclosureJan 28, 20258-K/AExecutive ChangeDec 19, 20248-KExecutive Change · Reg FD DisclosureNov 13, 202410-Q10-QNov 12, 20248-KReg FD Disclosure · Company UpdateSep 16, 202410-Q10-QAug 9, 20248-KResults of OperationsAug 9, 20248-KShareholder VoteJun 21, 20248-KReg FD DisclosureJun 3, 2024DEFA14ADEFA14AMay 29, 20248-KExecutive ChangeMay 29, 202410-Q10-QMay 7, 20248-KResults of OperationsMay 7, 2024DEFA14ADEFA14AApr 29, 2024DEF 14ADEF 14AApr 29, 20248-KExecutive ChangeApr 11, 20248-KReg FD DisclosureApr 9, 202410-K10-KFeb 27, 20248-KResults of OperationsFeb 27, 20248-KBylaw AmendmentFeb 15, 20248-KDelisting Notice · Executive ChangeJan 25, 20248-KReg FD Disclosure · Company UpdateJan 8, 2024SC 13GSC 13GNov 17, 202310-Q10-QNov 6, 20238-KResults of Operations · Reg FD DisclosureNov 6, 2023SC 13GSC 13GOct 10, 20238-KExecutive ChangeOct 6, 20238-KReg FD DisclosureSep 13, 20238-KReg FD DisclosureAug 9, 202310-Q10-QAug 9, 20238-KResults of OperationsAug 9, 20238-KBylaw Amendment · Shareholder VoteJun 16, 20238-KCompany UpdateJun 15, 2023424B5424B5Jun 15, 20238-KCompany UpdateJun 15, 20238-KReg FD Disclosure · Company UpdateJun 6, 20238-KReg FD Disclosure · Company UpdateJun 5, 20238-KReg FD Disclosure · Company UpdateMay 26, 2023DEFA14ADEFA14AMay 10, 202310-Q10-QMay 10, 20238-KResults of OperationsMay 10, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 20238-KReg FD Disclosure · Company UpdateApr 26, 20238-KReg FD Disclosure · Company UpdateApr 17, 2023
Insider Activity
In the 90 days to Feb 10, 2026: 1 insider bought $7.8M · 4 sold $10.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 10, 2026 | Vultaggio VincentPAO and PFO | Sell | 6,894 | $2.42 | $17K |
| Feb 9, 2026 | Vultaggio VincentPAO and PFO | Sell | 3,379 | $2.39 | $8K |
| Feb 9, 2026 | Eastland Julia MarieCEO & President | Sell | 889 | $2.39 | $2K |
| Feb 9, 2026 | Bruns IngmarChief Medical Officer | Sell | 335 | $2.39 | $801 |
| Feb 6, 2026 | Vultaggio VincentPAO and PFO | Sell | 29,951 | $2.43 | $73K |
| Feb 6, 2026 | Eastland Julia MarieCEO & President | Sell | 7,866 | $2.43 | $19K |
| Feb 6, 2026 | Bruns IngmarChief Medical Officer | Sell | 2,962 | $2.43 | $7K |
| Feb 3, 2026 | Vultaggio VincentPAO and PFO | Sell | 556 | $2.52 | $1K |
| Feb 2, 2026 | Vultaggio VincentPAO and PFO | Sell | 2,540 | $2.55 | $6K |
| Dec 31, 2025 | Walters William ThurmanTenPercentOwner | Buy | 6,459,973 | $1.20 | $7.8M |
| Dec 15, 2025 | Goel David E.TenPercentOwner | Sell | 7,500,000 | $1.33 | $10.0M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance